Related Experiment Video
Updated: Sep 27, 2025
07:41
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
2.6K
An Evidence-Based Staging System for Mucosal Melanoma: A Proposal.
ChuanLiang Cui1, Bin Lian1, XiaoShi Zhang2
1Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, 100142, China.
Annals of Surgical Oncology
|April 10, 2022
Summary
A new staging system for mucosal melanoma (MuM) was developed, showing significant differences in overall survival (OS) based on tumor depth, nodal status, and metastasis. This unified approach aims to improve MuM staging and clinical trial design.
Area of Science:
- Oncology
- Dermatology
- Pathology
Background:
- Mucosal melanoma (MuM) lacks a universally adopted staging system encompassing all anatomical sites.
- A unified staging approach is hypothesized to be feasible for MuM patients across different primary tumor locations.
Purpose of the Study:
- To develop and propose a single, unified staging system for mucosal melanoma.
- To harmonize the staging of MuM and facilitate clinical trial design.
Main Methods:
- Analysis of a prospective database of 1814 MuM patients with a median follow-up of 5.14 years.
- Calculation of overall survival (OS) from pathological diagnosis to death.
- Multivariate analyses using the Cox proportional hazard model to identify prognostic variables.
Main Results:
- Significant OS differences were observed for tumor invasion depth (T1 vs. T2/T3/T4), number of regional lymph nodes (N1 vs. N2), and distant metastasis sites (M1a-M1d).
- A proposed staging system categorizes MuM into Stages I, II, IIIA, IIIB, and IV with distinct median OS estimates.
- Median OS ranged from 4.3 years for Stage I (T1N0M0) to 0.9 years for Stage IV (TanyNanyM1).
Conclusions:
- A unified staging system for mucosal melanoma, incorporating all primary tumor sites, is proposed.
- This system can standardize MuM staging and improve the design and comparability of clinical trials.
